Clinical Trials Logo

Clinical Trial Summary

The purpose of this open-label study is to evaluate long-term safety and tolerability of LCZ696 in eligible heart failure with preserved ejection fraction (HFpEF) patients who completed PARAGON-HF in Japan.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03909295
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone +81337978748
Email novartis.email@novartis.com
Status Not yet recruiting
Phase Phase 3
Start date April 15, 2019
Completion date April 15, 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01989299 - Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction N/A
Not yet recruiting NCT03876223 - Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Recruiting NCT03843060 - A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers Phase 1
Completed NCT01714752 - Evaluation of Left Ventricular Filling Pressures During Exercise N/A
Not yet recruiting NCT03877224 - DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Phase 3